The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice

Empagliflozin, a sodium-glucose co-transporter 2 inhibitor developed, has been shown to reduce cardiovascular events in patients with type 2 diabetes and established cardiovascular disease. Several studies have suggested that empagliflozin improves the cardiac energy state which is a partial cause o...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jungmi, Matoba, Naoki, Setoyama, Daiki, Watanabe, Daiki, Ohnishi, Yuichiro, Yasui, Ryuto, Kitai, Yuichirou, Oomachi, Aki, Kotobuki, Yutaro, Nishiya, Yoichi, Pieper, Michael Paul, Imamura, Hiromi, Yanagita, Motoko, Yamamoto, Masamichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023657/
https://www.ncbi.nlm.nih.gov/pubmed/36932133
http://dx.doi.org/10.1038/s42003-023-04663-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023657/
https://www.ncbi.nlm.nih.gov/pubmed/36932133
http://dx.doi.org/10.1038/s42003-023-04663-y

Ejemplares similares